CIAM
TSHA icon

Caitong International Asset Management’s Taysha Gene Therapies TSHA Stock Holding History

Caitong International Asset Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.14K Sell
926
-24,651
-96% -$115K ﹤0.01% 1158
2025
Q4 		$141K Buy
25,577
+22,373
+698% +$109K 0.03% 302
2025
Q3 		$10.5K Buy
3,204
+1,057
+49% +$2.99K 0.01% 1002
2025
Q2 		$4.96K Buy
2,147
+1,333
+164% +$2.9K ﹤0.01% 1014
2025
Q1 		$1.13K Buy
+814
New +$1.36K ﹤0.01% 1536

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Caitong International Asset Management's TSHA Position: Q1 2026 in Review

Caitong International Asset Management reduced its Taysha Gene Therapies (TSHA) stake by 96% in Q1 2026, selling an estimated $115K and leaving 926 shares worth $4.14K. The position accounts for ﹤0.01% of the portfolio, ranked #1158.

Caitong International Asset Management first reported a position in TSHA in Q1 2025 and has held it in 5 quarters since. The position peaked at $141K in Q4 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Caitong International Asset Management held 926 shares of Taysha Gene Therapies worth $4.14K as of Q1 2026.
  • Caitong International Asset Management sold 24,651 Taysha Gene Therapies shares in Q1 2026, an estimated $115K.
  • Taysha Gene Therapies made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #1158 holding.
  • Caitong International Asset Management first reported a position in Taysha Gene Therapies in Q1 2025 and has held it in 5 quarters since.
  • Caitong International Asset Management's Taysha Gene Therapies position peaked at $141K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.